Pharmaceutical Business review

Bioniche Pharma wins FDA approval for generic KetalarCIII

The 10mg/ml strength joins Bioniche’s current offering of Ketamine in 50mg/ml and 100mg/ml strengths and completes its full product line offering. Bioniche plans to launch the 10mg/ml strength in October 2008.

Steve Thornton, CEO of Bioniche Pharma, said: “We are pleased to offer our customers a full line of ketamine for their treatment needs.”